What Researchers Did
This paper reviews the use of Dermagraft, a cell-based tissue-engineered product, in the treatment of chronic wounds, particularly diabetic foot ulcers.
What They Found
Dermagraft has received marketing approval in the United States for the treatment of diabetic foot ulcers. It is also actively being developed for venous leg ulcers and has been clinically applied for other wound healing indications.
What This Means for Canadian Patients
Currently, Dermagraft is approved for use in the United States for diabetic foot ulcers, but its availability for Canadian patients is not indicated by this study. Canadian patients with chronic wounds, such as diabetic foot ulcers, would need to consult their healthcare providers about available treatment options in Canada.
Canadian Relevance
This study has no direct Canadian connection as it focuses on Dermagraft's approval and use in the United States.
Study Limitations
The abstract does not present specific clinical trial data or comparative outcomes, limiting insights into Dermagraft's efficacy against other treatments.